SCHEMBL571026

SCHEMBL571026

CC1=C(C)C(=O)c2ccccc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC25B P30305 9/20 0.68
▸ CDC25A P30304 7/20 0.68
▸ AURKA O14965 1/20 0.68
▸ AURKB Q96GD4 1/20 0.68
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ S100A4 P26447 7/20 0.62
▸ MAOA P21397 3/20 0.61
▸ LMNA P02545 3/20 0.61
▸ MAPT P10636 3/20 0.61
▸ BLM P54132 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ POLB P06746 2/20 0.61
▸ RAB9A P51151 2/20 0.61
▸ PLIN1 O60240 2/20 0.61
▸ MAPK1 P28482 2/20 0.61
▸ PLIN5 Q00G26 2/20 0.61
▸ ABHD5 Q8WTS1 2/20 0.61
▸ APAF1 O14727 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29941466 1.00 CDC25B (0.68) CDC25BCDC25AAURKAAURKBMEN1
Water SCHEMBL8664586 0.97 CDC25B (0.65) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL15491792 0.94 CDC25B (0.62) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL17969766 0.89 CDC25B (0.58) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL8586117 0.86 S100A4 (0.60) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL1556617 0.86 CDC25B (0.60) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL10503148 0.85 CDC25B (0.54) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL13393574 0.84 AURKA (0.64) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL8914003 0.82 IDO1 (0.68) CDC25BCDC25AAURKAAURKBMEN1
SCHEMBL3414838 0.82 CDC25B (1.00) CDC25BCDC25AAURKAAURKBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105441371-B A kind of genetic engineering bacterium and its application in production Co-Q10 上虞新和成生物化工有限公司 2018-11-30 — — CN claimed
CN-105441371-A Genetically engineered bacteria and application thereof in production of coenzyme Q10 SHANGYU NHU BIOCHEMICAL IND CO LTD 2016-03-30 — — CN claimed
WO-2010014361-A1 NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI- INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES EDISON PHARMACEUTICALS, INC. (US) 2010-02-04 — — WO claimed
US-20100029784-A1 NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES AMPERE LIFE SCIENCES, INC. 2010-02-04 — — US claimed
US-20090297890-A1 Anode for Bioelectric Power Generation And Power Generation Method And Apparatus Utilizing Same EBARA CORPORATION (JP) 2009-12-03 — — US claimed
US-20090142627-A1 Biological Power Generator, and Method of Treating Organic Solid Pollutant-Containing Waste, a Method of Treating Organic Polymeric Substance-Containing Wastewater, a Method of Treating Organic Substance-Containing Wastewater, as Well as Apparatuses for Implementing These Treatment Methods EBARA CORPORATION (JP) 2009-06-04 — — US claimed
EP-1947716-A1 ANODE FOR BIOLOGICAL POWER GENERATION AND POWER GENERATION METHOD AND DEVICE UTILIZING IT EBARA CORPORATION (JP) 2008-07-23 — — EP claimed
EP-1939968-A1 BIOLOGICAL POWER PLANT, AND METHOD OF TREATING ORGANIC SOLID CONTAMINANT-CONTAINING WASTE, METHOD OF TREATING ORGANIC HIGH MOLECULAR SUBSTANCE-CONTAINING LIQUID WASTE AND METHOD OF TREATING ORGANIC SUBSTANCE-CONTAINING LIQUID WASTE BY USING THE BIOLOGICAL POWER PLANT, AND APPARATUS FOR CONDUCTING THESE METHODS EBARA CORPORATION (JP) 2008-07-02 — — EP claimed
JP-3251582-B2 — — 2002-01-28 — — JP claimed
EP-0570414-B1 NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION KS BIOMEDIX LTD (GB) 2000-07-05 — — EP claimed
EP-0275591-B1 PROCESS FOR THE SELECTIVE OXIDATIVE CARBONYLATION OF CONJUGATED DIENES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1992-01-29 — — EP claimed
US-4868328-A Selective oxidative carbonylation of conjugated dienes SHELL OIL COMPANY (US) 1989-09-19 — — US claimed
EP-0275591-A2 Process for the selective oxidative carbonylation of conjugated dienes SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-07-27 — — EP claimed
CN-87108385-A Process for the selective oxidative carbonylation of conjugated dienes — 1988-07-27 — — CN claimed
US-4575562-A CARBONYLATION, ESTERIFICATION, QUINONE OXIDANT, HYDROGENATION MONSANTO COMPANY (US) 1986-03-11 — — US claimed
EP-0152852-A2 Antimicrobial agent for treating buildings, building materials, textiles, leather, agricultural products and foodstuffs PÜHRINGER, Josef, Dr. (SE) 1985-08-28 — — EP claimed
US-4460674-A GALLIC ACID DERIVATIVES AND NAPOHTHOQUINONES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-07-17 — — US claimed
US-4220528-A CONTACTING A GAS WITH A SOLUTION CONTAINING A HYDRAZINE, A QUINONE, AN ALKALI; CONTACTING THE DEOXYGENATED GAS WITH WATER OTSUKA CHEMICAL CO., LTD. (JP) 1980-09-02 — — US claimed
US-4201588-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE EASTMAN KODAK COMPANY (US) 1980-05-06 — — US claimed
US-4195998-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, QUINONE OR CARBAZIDE PHOTOREDUCTANT EASTMAN KODAK COMPANY (US) 1980-04-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029784-A1 NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES NFE2L2, NQO1, POT1 CDC25B 970/4885CDC25A 697/4885AURKA 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback